179 results about "Extravasation" patented technology

The devices and methods shown provide for the minimization of extravasation during arthroscopic surgery. The anti-extravasation sheath allows a surgeon to drain excess fluids from the soft tissue surrounding the surgical field during arthroscopic surgical procedures.

Some embodiments of this disclosure relates to systems and methods for imaging a patient's vasculature. For example, near infrared (NIR) light can be used to illuminate a target area and light that is reflected or scattered from the target area can be used for generate an image of the target area. In some embodiments, the system can be configured such that the image shows the presence, absence, or extent of infiltration or extravasation in the target area. The system can be configured to document that presence, absence, or extend of infiltration or extravasation at an infusion site. In some embodiments, an imaging system can be mounted onto a patient so that the imaging system can monitor an infusion site, and the imaging system can be configured to automatically detect the presence of infiltration or extravasation.

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

This invention provides device for co-culturing at least two different cell types in a two-dimensional configuration, methods of patterning at least two different cell types in a two-dimensional co-culture configuration, and uses of these devices and methods for analyzing an effect of candidate compound on such cellular cocultures. Also provided is a transmigration and extravasation device. Assay devices for analyzing the absorption, permeability, metabolism and/or toxicity of a candidate compound by a cell are provided. A microfluidic network, which is adaptable for integration with a device for coculturing is provided.

Methods and compositions comprising GnRH-I and GnRH-II, GnRH-I and GnRH-II antibodies, anti-receptor antibodies, polynucleotide constructs and GnRH-I and GnRH-II analogs for immune enhancement and suppression, prevention and treatment of diseases and conditions characterized by abnormal T-cell activity, treatment of viral and prion-related diseases, and treatment of T-cell related neoplastic diseases are disclosed.

The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels. The surprisingly manifold pharmacological properties of the PL-conjugates allow for the invention, disclosed herein, of novel methods for the treatment of a diverse range of disease states, including obstructive respiratory disease, including asthma; colitis and Crohn's disease; central nervous system insult, including blood brain barrier compromise, ischemic stroke, and multiple sclerosis; contact dermatitis; psoriasis; cardiovascular disease, including ischemic conditions and prophylaxis for invasive vascular procedures; cellular proliferative disorders, including anti-tumor vasculogenesis, invasiveness, and metastases; anti-oxidant therapy; hemolytic syndromes; sepsis; acute respiratory distress syndrome; tissue transplant rejection syndromes; autoimmune disease; viral infection; and hypersensitivity conjunctivitis. The therapeutic methods of the invention include administration of phosphatidylethanolamine bound to carboxymethylcellulose, heparin, hyaluronic acid, polyethylene glycol, and Polygeline (haemaccel). Disclosed herein are also new compounds comprised of phospholipid moieties bound to low molecular weight monomers and dimers, including mono- and disaccharides, carboxylated disaccharides, mono- and dicarboxylic acids, salicylates, bile acids, and fatty acids.

Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.

Screws for anchoring in cancellous or other low-quality bone are described. One type of screw addresses the problem of extravasation of bone cement when filling an area of low-quality bone. The screw includes an expandable container for retaining bone cement and anchoring the screw in low-quality bone. The screw also includes an anchoring device for holding the screw in place in the bone while it is supplied with bone cement or other appropriate filler. The screw further includes a head for connecting to a rod or other apparatus. A second type of screw uses an expandable container to deform two or more fins to compress cancellous bone and/or anchor in cancellous bone.

The present invention provides an in vitro blood vessel model for investigation of drug induced vascular injury and other vascular pathologies. The in vitro blood vessel model provides two channels separated by a porous membrane that is coated on one side by an endothelial cell layer and is coated on the other side by a smooth muscle cell layer, wherein said model is susceptible to the extravasation of red blood cells across said porous membrane due to drug induced vascular injury.

Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM, leading to widespread shutdown of vascular flow, hemorrhage, and necrosis. PEM constructs are developed that incorporate large amounts of iron-containing protein, possess high oxygen affinities, and demonstrate delayed nitric oxide binding. Such properties induce selective NME of tumors after extravasation, and will likely enhance the effect of VEGFR TKIs and/or mTOR inhibitors.

The present invention relates to novel antagonists to a B₁-bradykinin (B₁-BK) receptor which have a good affinity and selectivity therefor, some of which being at least partially resistant to enzymatic degradation. The synthesis of the B₁ receptors is induced during inflammation. Symptoms associated with inflammation (elevated hydrostatic pressure and plasma leakage or extravasation) have been observed in diabetic animal models (streptozotocin-induced diabetes (STZ)) as well as in spontaneously hypertensive rats (SHR). The present inventors confirm the presence of B₁-BK receptors in these two models. B₁-BK antagonists abolished the vasocontraction induced by B₁-BK in SHR and STZ, and reduced the glycemia of diabetic animals to normal levels. The present B₁-antagonists are useful for treating any condition wherein B₁-receptor is expressed, particularly during inflammation, and more particularly wherein B₁-receptor expression results in diabetic vasculopathy, other diabetic symptoms associated with an insulitis and a post-capillary resistance building as a consequence of the presence of a B₁-receptor.

The invention discloses a medicament formula for relieving pain caused by infusion medicament and preventing phlebitis. The medicament formula can be used for relieving pain caused by intravenous supplementing potassium, infusion mannitol, azithromycin, fructose diphosphate sodium and chemotherapeutic medicaments, and can be used for effectively preventing and treating extravasation phlebitis caused by long-term use of a remaining needle, infusion of vein high-nutrition medicaments, infusion of chemotherapeutic medicaments, infusion extravasation and the like. According to the medicament formula, 20-35ng of anisodamine, 6-13ml of lidocaine, 15-26mg of dexamethasone and 4-6ml of glycerin are arranged in a sterile kidney basin, sterile gauze is coated above a puncture part after being uniformly wetted, and an external preservative film is wound on the gauze. The medicinal formula has the advantages of continually and efficiently relieving local pain caused by infusion medicaments, and effectively preventing and treating local inflammation, swelling pain and stripped cable change caused by infusion.

A tamper resistant guard for protectively covering a patient's infusion site while allowing visual inspection of the site without manipulation of the guard. A resilient base panel includes an open portion therein that is positioned over the infusion site, allowing visual inspection of the dermal tissue proximal of the site for indications of infiltration and extravasation of medications and degeneration of dermal tissues proximal to the infusion site. A resilient flap having a flexible window therein is hingedly secured to the base panel with the window positioned in register with the panel open portion, to facilitate visual inspection of the infusion site without flap manipulation. The flexible window is positioned in covering relationship over the infusion site and includes means for fastening a flap attaching side in overlapping orientation to secure infusion tubing between the flap and base panel, thereby preventing patient tampering with the tubing and the infusion site.

The present invention relates in certain embodiments to medical devices for treating vertebral compression fractures. In one embodiment, the invention relate to systems for introducing fill material into a vertebral body that slowly expands vertebral height without explosive balloon expansion as in kyphoplasty. The system provides a fill material that infills a vertebra without flowable bone cement as used in kyphoplasty and vertebropalsty procedures. Thus, the bone fill system prevents the possibility of extravasation of material into the spinal canal which occurs in a significant number of kyphoplasty and vertebropalsty procedures. An energy source can apply energy to a substantially rigid implant material in order to soften, melt, or fracture the implant material to infill a vertebral body.

The present invention is directed to compositions containing an anti-inflammatory compound that acts by blocking protein extravasation together with an NSAID. These compositions may be used to treat inflammation and pain, especially headache pain. The invention also includes methods in which these drugs are separately administered to a patient.

The present invention is directed to compositions containing a 5-HT_1F-specific agonist that acts by blocking protein extravasation together with an NSAID. These compositions may be used to treat migraine and headache pain. The invention also includes methods in which these drugs are separately administered to a patient.

The method for preventing extravasation of bone cement used in balloon kyphoplasty involves first forming a void in a vertebral body. A pair of unfilled balloons are then inserted into the void in the vertebral body. An injection tube or catheter is inserted through an inlet port of each of the balloons, and the balloons are filled with bone cement. The injection tubes are then removed from the inlet ports. The bone cement is preferably provided in the form of pellets or granules. The inlet ports are each provided with a seal, such as an elastic band mounted thereabout, or the like, allowing the inlet port to be automatically sealed as soon as the corresponding injection tube is withdrawn. The device includes at least the balloon and the seal, but may be furnished as a kit that also includes the bone cement and injection tube.

A use of an anti-inflammatory polysaccharides composition comprising fucans and galactans to inhibit the release of one or more of IL-8, PGE2 and VEGF by a cell activated during an inflammatory process and an anti-inflammatory composition comprising a ratio of brown algae fucans/red algae galactans of between about 2.5/1 (w/w) to about 40/1 (w/w), the galactans having a molecular weight higher than about 100 kDa, and the fucans having a molecular weight between about 0.1 kDa and 100 kDa.